What’s Really Exciting About ‘Female Viagra’

Tweet

<!–

–> August 25, 2015 Current Commentary Leave a reply

Company Email Subscribe Button    Company RSS Subscribe Button

red and white capsule against a detail of American paper currency
photo by David Goehring

People find all sorts of things stimulating.

Sure, there’s the wonted suspects, like pictures of attractive mob, especially in provocative clothing and poses. But likewise there’s also sporting events, freewill triumphs and crime sprees (Bonnie and Clyde, for instance, even when not played ~ means of Warren Beatty and Faye Dunaway). Even blackouts, for the period of which many a baby has been made, if fewer than reporters sometimes suggest.

Also currency. Maybe especially money.

So I ween it has now been conclusively proven that flibanserin, moreover known as Addyi and sometimes called the protracted-sought “female Viagra,” has the in posse to stimulate sexual desire in a subset of the population. According to the latest findings of the Food and Drug Administration, that subset is the peopling of premenopausal women suffering from unhandsome sexual desire. According to me, the subset be obliged to also include shareholders in Sprout Pharmaceuticals.

Last week, precisely two days after Sprout’s campaign to get FDA approval bore fruit, the company announced that it is being acquired ~ the agency of Valeant Pharmaceuticals. The deal’s excellence is $1 billion, roughly 10 state of things what it reportedly cost to gain flibanserin to market.

I am disposed to bet that there was celebrating of entirely sorts among Sprout shareholders last week.

Not that I begrudge them, or anyone, an active and fulfilling sex life. If flibanserin brings relief to women who are unhappy by their level of sexual desire, great. If the scientific evidence had supported the business-off between the drug’s purported benefits and its lateral effects, I would have been joyful to join those urging FDA approval. If the benefits in freedom from disease and happiness outweighed its financial costs, I would lack to see it widely covered through prescription drug plans – at minutest as well covered as Viagra and other male animal libido enhancers, whose advertising we can hardly escape these days.

Unfortunately, those verge effects and those costs are both substantial, and the purported benefits are much less so. The reactions associated with Addyi, according to the FDA, hold low blood pressure, fatigue, vertigo and qualm, among others. And the potential interaction with alcohol is serious enough that the FDA requires prescribers to be certified with a risk evaluation program, completing a breeding program and counselling patients seriously relating to the risk of drinking while taking Addyi. In contrast, the drug’s effectiveness in trials because the condition it is designed to banquet was about one more sexually satisfying conflict per month.

The National Women’s Health Network, a nonprofit that campaigned in preparation for Addyi, cited the poor scientific favor for the drug’s efficacy at the same time that the most important factor in its resolution to work against Addyi’s taking. Cindy Pearson, the organization’s executive director, told BuzzFeed News, “The premises were awful, just awful.” Adriane Fugh-Berman, a pharmacology professor at Georgetown University, told The Washington Post Addyi’s approval was “a cheerless day for drug regulation.”

“What has been knowing since the last disapproval is that it has to a greater degree risks than we thought and it doesn’t accept any more benefits,” Fugh-Berman related. “This opens the way with respect to drug companies to pressure the FDA through public relations campaigns to approve other thing bad drugs.”

Then there’s the require to be paid. The New York Times reported that Addyi is projected to require to be paid about $400 a month without assurance, and notes that it is unclear to what extent many insurers will pay for the remedy. While supporters of Addyi were prosperous in framing its acceptance as a civil issue before the FDA, insurers may observe it as purely a lifestyle returns, rather than as a medical handling.

This ambiguity is likely to subsist bolstered by those who question whether the plight Addyi is said to treat, hypoactive sexual wish for disorder, is simply a way to pathologize ordinary human variation in libido in family to sell drugs. David Jay, who wrote a beg on Change.org on behalf of a reticulated of activists to urge the FDA not to value Addyi, said to Newsweek, “The scary act about this drug is that the indisposition it treats can be spread by marketing dollars.” Some opponents are concerned that women who would not in other respects be distressed will be pressured to be conscious of being shame or discomfort about their sexual appetites in regular government to increase the potential patient – and purchaser – pool for Addyi and its unavoidable future competitors.

But for all the skepticism, we can no longer argue that flibanserin does not arouse excitement among some people, female or staminate. They just need to be in the calling of selling it.

Print pagePDF page

<!– –> <!– –> Pin It

Addyi, Flibanserin, Food And Drug Administration, Medicine, Pharmaceuticals, Science, Sprout Pharmaceuticals

en  English

es  Español

pt-br  Português

Larry M. Elkin, CPA, CFP®

Larry M. Elkin, CPA, CFP®

Larry M. Elkin, CPA, CFP®, has on condition personal financial and tax counseling to a sophisticated henchman base since 1986. After six years through Arthur Andersen, where he was a senior … Read Full

More posts ~ dint of. the Author »

Related Posts:

Protecting Apes Can Make Us Better People

Maine’s Foreign Policy On Prescription Drugs

Political Medicine

All Uber, Or Uber Alles?

Another Problem For LTC Insurance: Earlier Alzheimer’s Diagnosis

Recent Posts

What’s Really Exciting About ‘Female Viagra’

Eric Meermann and Tim Meyer in the Fairfield County Business Journal

Another Market Tantrum

Eric Meermann in Clark Howard

Paul Jacobs in The Street

Calendar

August 2015

M

T

W

T

F

S

S

« Jul

 

 

 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

 

Contact Us

Your Name (required)

Your Email (required)

Subject

Your Message

Maybe it’s once for all going to get the coverage it deserves.

Recent Comments

    Archives